Home
CORT
CORT News

Latest Corcept Therapeutics Incorporated (CORT) News on April 2, 2025

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

Insider Monkey

15 hours ago

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement

Clinical Trials Arena

16 hours ago

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement

MT Newswires

a day ago

Equity Markets Mixed Ahead of Tariff Announcements

Why Is Corcept (CORT) Stock Soaring Today

StockStory

a day ago

Why Is Corcept (CORT) Stock Soaring Today

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

Simply Wall St.

a day ago

Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip

MT Newswires

a day ago

Top Midday Gainers

NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute

Yahoo Finance Video

a day ago

NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute

MT Newswires

a day ago

Piper Sandler Raises Corcept Therapeutics' Price Target to $128 From $78, Maintains Overweight Rating

MT Newswires

2 days ago

Sector Update: Health Care Stocks Fall Pre-Bell Monday

MT Newswires

2 days ago

Sector Update: Health Care

MT Newswires

2 days ago

Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Business Wire

2 days ago

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?

Zacks

4 days ago

Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?

3 Reasons to Sell CORT and 1 Stock to Buy Instead

StockStory

6 days ago

3 Reasons to Sell CORT and 1 Stock to Buy Instead

Argus Research

7 days ago

CORT: Raising target price to $76.00

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

Zacks

12 days ago

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

3 Growth Stocks in Hot Water

StockStory

14 days ago

3 Growth Stocks in Hot Water

1 Small-Cap Stock on Our Buy List and 2 to Avoid

StockStory

19 days ago

1 Small-Cap Stock on Our Buy List and 2 to Avoid

Top Growth Companies With Significant Insider Ownership

Simply Wall St.

22 days ago

Top Growth Companies With Significant Insider Ownership

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Business Wire

23 days ago

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Zacks

25 days ago

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?

Zacks

a month ago

Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock?

Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye

Simply Wall St.

a month ago

Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye

Argus Research

a month ago

CORT: Lowering target price to $59.00

Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

a month ago

Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

StockStory

a month ago

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

StockStory

a month ago

Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers

MT Newswires

a month ago

Corcept Therapeutics Says New Drug Application for Cushing's Syndrome Treatment Filed by FDA

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Business Wire

a month ago

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)

Zacks

a month ago

3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT)

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?

Zacks

a month ago

Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year?

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price

Simply Wall St.

a month ago

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 48% Above Its Share Price

Why Corcept (CORT) Shares Are Sliding Today

StockStory

a month ago

Why Corcept (CORT) Shares Are Sliding Today

CORT's Q4 Earnings and Revenues Fall Short of Estimates

Zacks

a month ago

CORT's Q4 Earnings and Revenues Fall Short of Estimates

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Zacks

a month ago

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Thomson Reuters StreetEvents

a month ago

Q4 2024 Corcept Therapeutics Inc Earnings Call

Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com

a month ago

Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Zacks

a month ago

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Associated Press Finance

a month ago

Corcept: Q4 Earnings Snapshot

MT Newswires

a month ago

Corcept Q4 Net Income Lower, Revenue Rises; Sets Guidance

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

StockStory

a month ago

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

Business Wire

a month ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

Argus Research

a month ago

CORT: Lowering target price to $64.00

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

StockStory

a month ago

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Insider Monkey

a month ago

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Argus Research

a month ago

CORT: Raising target price to $76.00

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

Investor's Business Daily

a month ago

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

Incyte Stock Sees Relative Strength Rating Rise To 71

Investor's Business Daily

a month ago

Incyte Stock Sees Relative Strength Rating Rise To 71

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

Business Wire

2 months ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

3 US Growth Companies With High Insider Ownership Expecting Up To 22% Revenue Growth

Simply Wall St.

2 months ago

3 US Growth Companies With High Insider Ownership Expecting Up To 22% Revenue Growth

Argus Research

2 months ago

CORT: Raising target price to $70.00

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

Zacks

2 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

Zacks

2 months ago

Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Zacks

2 months ago

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham

Zacks

2 months ago

Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham

All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy

Zacks

2 months ago

All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy

Buy These 5 Stocks With Recent Price Strength Amid a Volatile January

Zacks

2 months ago

Buy These 5 Stocks With Recent Price Strength Amid a Volatile January

Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks

2 months ago

Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"

Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?

Zacks

2 months ago

Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?

Medical Stock Soars To Highs As Cortisol Screening Grows

Investor's Business Daily

2 months ago

Medical Stock Soars To Highs As Cortisol Screening Grows

Argus Research

2 months ago

CORT: Raising target price to $64.00

Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)

Insider Monkey

2 months ago

Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?

Insider Monkey

2 months ago

Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years?

Argus Research

3 months ago

CORT: What does Argus have to say about CORT?

Discover 3 US Growth Stocks With Strong Insider Ownership

Simply Wall St.

3 months ago

Discover 3 US Growth Stocks With Strong Insider Ownership

Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance

Insider Monkey

3 months ago

Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance

Corcept Submits Application for Another Cushing's Syndrome Drug

Zacks

3 months ago

Corcept Submits Application for Another Cushing's Syndrome Drug

MT Newswires

3 months ago

Corcept Therapeutics Files New Drug Application for Relacorilant

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Business Wire

3 months ago

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?

Insider Monkey

3 months ago

Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025?

Argus Research

3 months ago

CORT: Lowering target price to $53.00

Argus Research

3 months ago

CORT: Lowering target price to $58.00

Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial

Clinical Trials Arena

4 months ago

Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial

MT Newswires

4 months ago

Corcept Therapeutics' Phase 3 Study of Relacorilant Shows Improvements in Patients With Hypercortisolism

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Business Wire

4 months ago

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

Benzinga

4 months ago

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

MT Newswires

4 months ago

Corcept Therapeutics Phase 4 Trial of Korlym Shows Hemoglobin A1c Reduction in Patients With Hypercortisolism, Diabetes

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

Business Wire

4 months ago

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Zacks

4 months ago

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT Newswires

4 months ago

Corcept Phase 2 Trial of Dazucorilant for Amyotrophic Lateral Sclerosis Fails to Meet Primary Endpoint

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

Business Wire

4 months ago

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

Investor's Business Daily

4 months ago

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

Zacks

4 months ago

Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock

Argus Research

4 months ago

CORT: Lowering target price to $62.00

Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why

Zacks

4 months ago

Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Zacks

4 months ago

Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?

Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?

Zacks

4 months ago

Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?

3 US Stocks With High Insider Ownership And Up To 79% Growth

Simply Wall St.

4 months ago

3 US Stocks With High Insider Ownership And Up To 79% Growth

Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?

Zacks

4 months ago

Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?

Argus Research

4 months ago

CORT: Raising target price to $63.00

Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years

Simply Wall St.

4 months ago

Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

Zacks

4 months ago

Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?

Argus Research

4 months ago

CORT: Rating decreased to a HOLD

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Zacks

4 months ago

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Corcept Shares Rise More Than 60% in Three Months: Here's Why

Zacks

4 months ago

Corcept Shares Rise More Than 60% in Three Months: Here's Why

3 Reasons Growth Investors Will Love Corcept (CORT)

Zacks

4 months ago

3 Reasons Growth Investors Will Love Corcept (CORT)

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

Zacks

4 months ago

Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet

Argus Research

5 months ago

CORT: Rating decreased to a HOLD

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Zacks

5 months ago

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use